Pharmaceutical - Production, Neurological


Current filters:


Popular Filters

FDA clears Eisai Zonegran facility in UK for US exports

FDA clears Eisai Zonegran facility in UK for US exports


Eisai says the US Food and Drug Administration has approved the US supply of the epilepsy drug Zonegran…

EisaiEuropeNeurologicalNorth AmericaPharmaceuticalProductionRegulationZonegran

Eisai's EMEA operation cleared as US supplier of Fycompa in USA


The US Food and Drug Administration has approved the US supply of Japanese pharma major Eisai's (TYO:…

EisaiFycompaNeurologicalNorth AmericaPharmaceuticalProduction

AAA enters supply deal with Eli Lilly for Amyvid in France, Italy and Spain


France-based molecular nuclear medicine firm Advanced Accelerator Applications (AAA) says it has signed…

Advanced Accelerator ApplicationsAmyvidEli LillyNeurologicalPharmaceuticalProduction

Japan's Eisai to set up parenteral facility in China


Japanese drug major Eisai (TYO; 4523) says that it has decided to establish a new parenteral facility…


FDA sends CRL rejecting Allergan's migraine drug Levadex on quality issues


US drugmaker Allergan (NYSE: AGN) said yesterday (April 16) that the US Food and Drug Administration…

AllerganLevadexNeurologicalNorth AmericaPharmaceuticalProductionRegulation

Shasun and Debiopharm ink deal for Huperzine-A


Swiss independent drug developer Debiopharm has entered into an accord with India-based contract manufacturer…

DebiopharmHuperzine-ALicensingNeurologicalPharmaceuticalProductionShasun Pharmaceuticals

Sanofi and Transgene collaborate on immunotherapy treatments; NAS designation of Aubagio disputed


Drug major Sanofi (Euronext: SAN) and fellow France-based biotech firm Transgene SA (NYSE-Euronext: TNG)…


Tackling opioid drug abuse through new delivery methods and post-marketing studies


The opioid pain management market will continue to evolve over the coming years with new products and…

NeurologicalNorth AmericaPharmaceuticalProductionRegulation

Another stumbling block for Impax Pharma's Rytary


Impax Pharmaceuticals, the branded products division of Impax Laboratories (Nasdaq: IPXL), revealed on…

GlaxoSmithKlineImpax LaboratoriesNeurologicalNorth AmericaPharmaceuticalProductionRegulationRytary

News briefs: Eli Lilly expands insulin facility; and Sanofi criticized over Lemtrada


US drug major Eli Lilly (NYSE: LLY) has announced a $140 million expansion to the company's Indianapolis…

BiotechnologyDiabetesEli LillyLemtradaNeurologicalPharmaceuticalPricingProductionSanofi

Back to top